AMENDMENTS TO THE CLAIMS

- 1. (Currently Amended) An isolated polypeptide having at least 80% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino</u> acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);
- (b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;
- (b)(e) the amino acid sequence of the extracellular domain of the polypeptide <u>having the</u> amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or
- (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or
- (c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

- 2. (Currently Amended) The isolated polypeptide of Claim 1 having at least 85% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino</u> acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);
- (b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;
- (b)(e) the amino acid sequence of the extracellular domain of the polypeptide <u>having the</u> amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or
- (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or
- (c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

- 3. (Currently Amended) The isolated polypeptide of Claim 1 having at least 90% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino</u> acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);
- (b) the amino acid-sequence of the polypeptide shown in Figure 10 (SEQ-ID-NO: 10), lacking its associated signal peptide;
- (b)(e) the amino acid sequence of the extracellular domain of the polypeptide <u>having the</u> amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or
- (d) the amino acid-sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or
- (c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

- 4. (Currently Amended) The isolated polypeptide of Claim 1 having at least 95% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino</u> acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);
- (b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;
- (b)(e) the amino acid sequence of the extracellular domain of the polypeptide <u>having the</u> amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or
- (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or

(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

- 5. (Currently Amended) The isolated polypeptide of Claim 1 having at least 99% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino</u> acids 34-321 of shown in Figure 10 (SEQ ID NO: 10);
- (b) the amino acid-sequence of the polypeptide shown in Figure 10 (SEQ-ID-NO: 10), lacking its associated signal peptide;
- (b)(e) the amino acid sequence of the extracellular domain of the polypeptide <u>having the</u> amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or
- (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEO ID NO: 10), lacking its associated signal peptide; or
- (c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922;

wherein said isolated polypeptide is more highly expressed in normal lung tissue compared to lung tumor, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal lung tissue compared to lung tumor.

- 6. (Currently Amended) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino</u> acids 34-321 of shown in Figure 10 (SEO ID NO: 10);
- (b) the amino acid sequence of the polypeptide shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide;
- (b)(e) the amino acid sequence of the extracellular domain of the polypeptide <u>having the</u> amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10; or
- (d) the amino acid sequence of the extracellular domain of the polypeptide of shown in Figure 10 (SEQ ID NO: 10), lacking its associated signal peptide; or

(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922.

- 7. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide <u>having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10)</u>.
 - 8. (Canceled).
- 9. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the extracellular domain of the polypeptide <u>having the amino acid sequence of amino acids 34-321 of shown in Figure 10 (SEQ ID NO: 10) wherein said extracellular domain is amino acids 81-109 or 232-253 of SEQ ID NO: 10.</u>
 - 10. (Canceled).
- 11. (Original) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209922.
- 12. (Original) A chimeric polypeptide comprising a polypeptide according to Claim 1 fused to a heterologous polypeptide.
- 13. (Original) The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.